In conclusion, our screening analyses to evaluate the pharmacological effects of novel GPR18 ligands indicated the impact on locomotor activity, depression- and anxiety-like symptoms, and pain threshold, and are similar to those of CB receptor activation. The gene discussed is GPR18; the disease is depressive symptom measurement.